NL-OMON44072
Completed
Not Applicable
Multi-center, randomized clinical trial to study the impact of in-hospital guidance for acutely decompensated heart failure treatment by predefined NT-proBNP targets (>30% reduction in NT-proBNP during admission) on the reduction of readmission rates and mortality - Prima II
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- acutely decompensated heart failure
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 362
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Hospital admission because of clinically validated acutely decompensated heart failure.
- •2\. Elevated NT\-proBNP levels \*1700 ng/L (\*200 pmol/L) on hospital admission.
- •3\. Written informed consent to participate in this study prior to any study procedures
Exclusion Criteria
- •1\. Severe Chronic Obstructive Pulmonary Disease (COPD) with FEV\<1l/min.
- •2\. Pulmonary embolism within 1 month prior to admission and pulmonary hypertension not caused by left ventricle dysfunction (LVD).
- •3\. Patients undergoing Continue Ambulant Peritoneal Dialysis (CAPD)/ Haemodialysis patients.
- •4\. Patients with planned Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI), Cardiac Resynchronization Therapy (CRT) and/or valvular surgery before admission (until one day before admission).
- •5\. Patients with planned Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI), Cardiac Resynchronization Therapy (CRT) and/or valvular surgery during admission until the moment of randomization
- •6\. Patient with a history of ST\-segment\-Elevated Myocardial Infarction (STEMI), CABG, PCI, CRT and/or valvular surgery within 1 month prior to admission.
- •7\. Patients in cardiogenic shock at admission requiring invasive treatment.
- •8\. Signed informed consent for any current interventional study.
- •9\. Presence of severe non\-cardiac related life\-threatening disease before inclusion with an expected survival of less than 6 months after inclusion.
- •10\. Mental of physical status not allowing written informed consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
FMT for Crohn's disease (FEMTRAC) studyCrohn's diseaseD003424JPRN-jRCTs041190022Ohmiya Naoki50
Not yet recruiting
Not Applicable
A multicenter randomized controlled trial on the treatment of snake string ulcer with liver and gallbladder fire excess syndrome usingITMCTR2024000117liuzhiyong
Active, not recruiting
Not Applicable
Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinomaEUCTR2015-001801-15-ESFIBICO
Completed
Not Applicable
A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitisComplicated diverticular diseaseinfection of diverticula10013535NL-OMON32858Academisch Medisch Centrum533
Completed
Not Applicable
A multicentre, randomised clinical trial to evaluate the efficacy of oral ciprofloxacin, oral tamsulosin, and the combination of oral ciprofloxacin and oral tamsulosin for the treatment of Chronic Prostatitis/Chronic Pelvic Pain SyndromeISRCTN85291415ational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIDDK, NIH) (USA)184